Redeye updates its estimates and valuation following Lifco releasing its Q1 2025 report. Sales slightly beat our estimates on the back of solid organic growth, while mix effects resulted in a slight margin miss. Year-to-date M&A volume aligns with our projections. Myriad economic uncertainties continue to muddy Lifco’s short-term outlook, though we remain confident in the company’s long-term performance.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/